Endocyte (Endocyte) Momentum Rank : 0 (As of May. 06, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Endocyte Momentum Rank?

Endocyte has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Endocyte Momentum Rank Related Terms

Thank you for viewing the detailed overview of Endocyte's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Endocyte (Endocyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.endocyte.com

Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.

Executives

Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin	director	ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy	officer: General Counsel	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour	officer: Chief Medical Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin	director
Michael T. Andriole	officer: Chief Financial Officer	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell	director	41 MOORES RD., FRAZER PA 19355
Beth Taylor	officer: VP Finance & Chief Acctg Off	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman	director, officer: President and CEO	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton	director	400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy	officer: VP of Regulatory Affairs	C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek	officer: Chief Commercial Officer	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906